References
- Adam R.D.: Giardia duodenalis: Biology and Pathogenesis. Clinical Microbiology Reviews. 34(4), e00024–19 (2021) doi: 10.1128/CMR.00024-19
- Alday P.H., Bruzual I., Nilsen A., Pou S., Winter R., Ben Mamoun C., Riscoe M.K., Doggett J.S.: Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii. Antimicrob Agents Chemother. 61(2) e01866–16 (2017) doi: 10.1128/AAC.01866-16
- Allain T., Amat C.B., Motta J.P., Manko A., Buret A.G.: Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota. Tissue Barriers. 5(1), e1274354 (2017) doi: 10.1080/21688370.2016.1274354
- Alshahethi M.A., Al-Hadheq A.A., Edrees W.H., Abdullah Q.Y., Al-Awar M.S.: Cutaneous leishmaniasis among attending hospitals and health centers in amran governorate, yemen. Electronic Journal of University of Aden for Basic and Applied Sciences. 5(3) 269–276 (2024) doi: 10.47372/ejua-ba.2024.3.373
- Amelo W. and Makonnen E.: Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges. BioMed Research International. 2021(1), 5539544 (2021) doi: 10.1155/2021/5539544
- Andriantsoanirina V., Khim N., Ratsimbasoa A., Witkowski B., Benedet C., Canier L., Bouchier C., Tichit M., Durand R., Ménard D.: Plasmodium falciparum Na+/H+ Exchanger (pfnhe-1) Genetic Polymorphism in Indian Ocean Malaria-Endemic Areas. The American Journal of Tropical Medicine and Hygiene. 88(1), 37 (2013) doi: 10.4269/ajtmh.2012.12-0359
- Ángeles-Arvizu A., Enriquez-Flores S., Jiménez-Gutiérrez A., Pérez-Rangel A., Luna-Arias J.P., Castillo-Romero A., Hernández J.M., León-Avila G.: MDR1 protein (ABC-C1) Over Expression in Giardia Intestinalis Incubated with Albendazole and Nitazoxanide. Acta Parasit. 66(4) 1158–1166 (2021) doi: 10.1007/s11686-021-00385-5
- Argüello-García R., Cruz-Soto M., González-Trejo R., Paz-Maldonado L.M.T., Bazán-Tejeda M.L., Mendoza-Hernández G., Ortega-Pierres G.: An antioxidant response is involved in resistance of Giardia duodenalis to albendazole. Front Microbiol. 6, 286 (2015) doi: 10.3389/fmicb.2015.00286
- Asare K.K., Africa J., Mbata J., Opoku Y.K.: The emergence of chloroquine-sensitive Plasmodium falciparum is influenced by selected communities in some parts of the Central Region of Ghana. Malar. J. 20(1) 447 (2021) doi: 10.1186/s12936-021-03985-8
- Avcı K.D., Karakuş M., Kart Yaşar K.: Molecular survey of pfmdr-1, pfcrt, and pfk13 gene mutations among patients returning from Plasmodium falciparum endemic areas to Turkey. Malar J. 23(1) 286 (2024) doi: 10.1186/s12936-024-05107-6.
- Babokhov P., Sanyaolu A.O., Oyibo W.A., Fagbenro-Beyioku A.F., Iriemenam N.C.: A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathogens and Global Health. 107(5) 242–252 (2013) doi: 10.1179/2047773213Y.0000000105
- Baina M.T., Djontu J.C., Mbama Ntabi J.D., Mfoutou Mapanguy C.C., Lissom A., Vouvoungui C.J., Boumpoutou R.K., Mouanga A.M., Nguimbi E., Ntoumi F.: Polymorphisms in the Pfcrt, Pfmdr1, and Pfk13 genes of Plasmodium falciparum isolates from southern Brazzaville, Republic of Congo. Sci Rep. 14(1), 27988 (2024) doi: 10.1038/s41598-024-78670-2
- Balaji S.N., Deshmukh R., Trivedi V.: Severe malaria: Biology, clinical manifestation, pathogenesis and consequences. Journal of Vector Borne Diseases. 57(1) 1 (2020) doi: 10.4103/0972-9062.308793
- Berberian D.A.: Treatment and prophylaxis of malaria with aralen. J Palest Arab Med Assoc. 2(6) 143–151 (1947)
- Bisetegn H., Zeleke A.J., Gadisa E., Shumie G., Damte D., Fenta T., Behaksra S., Bayih A.G.: Clinical, parasitological and molecular profiles of Cutaneous Leishmaniasis and its associated factors among clinically suspected patients attending Borumeda Hospital, North-East Ethiopia. PLoS Negl Trop Dis. 14(8) e0008507 (2020) doi: 10.1371/journal.pntd.0008507
- Black M.W. and Boothroyd J.C.: Lytic Cycle of Toxoplasma gondii. Microbiol Mol Biol Rev. 64(3) 607–623 (2000) doi: 10.1128/MMBR.64.3.607-623.2000
- Bogacz J.: 1954. [Comparative effect of various synthetic agents and various antibiotics, including spiramycin, on Toxoplasma]. Bull Soc Pathol Exot Filiales. 47(6) 903–915
- Bouteille B., Oukem O., Bisser S., Dumas M.: Treatment perspectives for human African trypanosomiasis. Fundamental & Clinical Pharmacology. 17(2) 171–181 (2003) doi: 10.1046/j.1472-8206.2003.00167.x
- Bridges D.J., Gould M.K., Nerima B., Mäser P., Burchmore R.J.S., Koning H.P.: Loss of the High-Affinity Pentamidine Transporter Is Responsible for High Levels of Cross-Resistance between Arsenical and Diamidine Drugs in African Trypanosomes. Mol Pharmacol. 71(4) 1098–1108 (2007) doi: 10.1124/mol.106.031351
- Büscher P., Cecchi G., Jamonneau V., Priotto G.: Human African trypanosomiasis. Lancet. 390(10110) 2397–2409 (2017) doi: 10.1016/S0140-6736(17)31510-6
- Camuset G., Remy V., Hansmann Y., Christmann D., Gomes de Albuquerque C., Sena Casseb G.A.: [Mucocutaneous leishmaniasis in Brazilian Amazonia]. Med Mal Infect. 37(6) 343–346 (2007) doi: 10.1016/j.medmal.2007.03.012.
- Carnielli J.B.T., Monti-Rocha R., Costa D.L., Molina Sesana A., Pansini L.N.N., Segatto M., Mottram J.C., Costa C.H.N., Carvalho S.F.G., Dietze R.: Natural Resistance of Leishmania infantum to miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil. Am J Trop Med Hyg. 101(4) 789–794 (2019) doi: 10.4269/ajtmh.18-0949
- CDC. 2019. CDC – DPDx – Amebiasis.
https://www.cdc.gov/dpdx/amebiasis/index.html. [accessed 2024 Aug 27] - CDC. 2024a. CDC – DPDx – Malaria.
https://www.cdc.gov/dpdx/malaria/index.html. [accessed 2024 Aug 26] - CDC. 2024b. Appendix A: Malaria in the United States: Treatment Tables. Malaria.
https://www.cdc.gov/malaria/hcp/clinical-guidance/malaria-treatment-tables.html. [accessed 2024 Sep 7] - CDC. 2024c. About Toxoplasmosis. Toxoplasmosis.
https://www.cdc.gov/toxoplasmosis/about/index.html. [accessed 2024 Sep 15] - CDC. 2024d. Clinical Care of Human African Trypanosomiasis. Sleeping Sickness (African Trypanosomiasis).
https://www.cdc.gov/sleeping-sickness/hcp/clinical-care/index.html [accessed 2024 Sep 9] - CDC. 2024e. Patient Care for Giardia Infection. Giardia.
https://www.cdc.gov/giardia/hcp/clinical-care/index.html. [accessed 2024 Sep 15] - Cernikova L., Faso C., Hehl A.B.: Five facts about Giardia lamblia. PLOS Pathogens. 14(9) e1007250 (2018) doi: 10.1371/journal.ppat.1007250
- Certad G., Viscogliosi E., Chabé M., Cacciò S.M.: Pathogenic Mechanisms of Cryptosporidium and Giardia. Trends in Parasitology. 33(7) 561–576 (2017) doi: 10.1016/j.pt.2017.02.006
- Ciuca L., Pepe P., Bosco A., Caccio S.M., Maurelli M.P., Sannella A.R., Vismarra A., Cringoli G., Kramer L., Rinaldi L., et al. Effectiveness of Fenbendazole and Metronidazole Against Giardia Infection in Dogs Monitored for 50-Days in Home-Conditions. Front Vet Sci. 8 626424 (2021) doi: 10.3389/fvets.2021.626424
- Cowell A.N., Winzeler E.A.: The genomic architecture of anti-malarial drug resistance. Brief Funct Genomics. 18(5) 314–328 (2019) doi: 10.1093/bfgp/elz008
- Cui Z., Li J., Chen Y., Zhang L.: Molecular epidemiology, evolution, and phylogeny of Entamoeba spp. Infection, Genetics and Evolution. 75, 104018 (2019) doi: 10.1016/j.meegid.2019.104018
- Dama S., Diakite B., Dinkorma O.T., Niangaly A., Kone A.K., Dara A., Kone A., Bamadio A., Kodio A., Doumbia D., et al.: Dynamics of Pfcrt K76T and Pfmdr1N86Y fifteen years after the withdrawal of chloroquine in Mali. AJPME. 2(1), 0–0 (2024) doi: 10.35995/ajpme2010004
- Doliwa C., Escotte-Binet S., Aubert D., Sauvage V., Velard F., Schmid A., Villena I.: Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters. Parasite. 20, 19 (2013) doi: 10.1051/parasite/2013020
- Dubey J.P.: Toxoplasmosis of Animals and Humans. 3rd ed. Boca Raton: CRC Press. (2021)
- Dubey J.P. and Jones J.L.: Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol. 38(11) 1257–1278 (2008) doi: 10.1016/j.ijpara.2008.03.007
- Dunay I.R., Gajurel K., Dhakal R., Liesenfeld O., Montoya J.G.: Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice. Clin Microbiol Rev. 31(4), e00057–17 (2018) doi: 10.1128/CMR.00057-17
- Faucher B., Pomares C., Fourcade S., Benyamine A., Marty P., Pratlong L., Faraut F., Mary C., Piarroux R., Dedet J.P., et al.: Mucosal Leishmania infantum leishmaniasis: specific pattern in a multicentre survey and historical cases. J Infect. 63(1), 76–82 (2011) doi: 10.1016/j.jinf.2011.03.012
- Reed D.A., Nomura T., Talley A.K., Cooper R.A., Dzekunov S.M., Ferdig M.T., Ursos L.M., Sidhu A.B., Naudé B., Deitsch K.W., et al.: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 6(4), 861–871 (2000) doi: 10.1016/s1097-2765(05)00077-8
- Franco J.R., Priotto G., Paone M., Cecchi G., Ebeja A.K., Simarro P.P., Sankara D., Metwally S.B.A., Argaw D.D.: The elimination of human African trypanosomiasis: Monitoring progress towards the 2021–2030 WHO road map targets. PLOS Neglected Tropical Diseases 18(4), e0012111 (2024) doi: 10.1371/journal.pntd.0012111
- Gelaw Y.M., Dagnew G.W., Alene G.D., Gangneux J.P., Robert-Gangneux F.: Toxoplasma gondii seroprevalence among pregnant women in Africa: A systematic review and meta-analysis. PLOS Neglected Tropical Diseases. 18(5), e0012198 (2024) doi: 10.1371/journal.pntd.0012198
- Ghosal A., Sardar S.K., Haldar T., Maruf M., Saito-Nakano Y., Dutta S., Nozaki T., Ganguly S.: Genotyping and epidemiological distribution of diarrhea-causing isolates of Giardia duodenalis in southeastern part of West Bengal, India. Parasitol Res. 122(11), 2567–2584 (2023) doi: 10.1007/s00436-023-07956-7.44
- Gibb H., Devleesschauwer B., Bolger P.M., Wu F., Ezendam J., Cliff J., Zeilmaker M., Verger P., Pitt J., Baines J., et al. World Health Organization estimates of the global and regional disease burden of four foodborne chemical toxins, 2010: a data synthesis. F1000Res. 4, 1393 (2015) doi: 10.12688/f1000research.7340.1
- Gil J.P. and Fançony C.: Plasmodium falciparum Multidrug Resistance Proteins (pfMRPs). Front Pharmacol. 12 (2021) doi:
10.3389/fphar.2021.759422 [accessed 2024 Aug 31]
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.759422/full - Keating G.M.: Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 73, 1951–1966 (2013)
https://doi.org/10.1007/s40265-013-0143-y - Graf F.E., Ludin P., Wenzler T., Kaiser M., Brun R., Pyana P.P., Büscher P., Koning H.P. de, Horn D., Mäser P.: Aquaporin 2 Mutations in Trypanosoma brucei gambiense Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Melarsoprol. PLOS Neglected Tropical Diseases. 7(10), e2475 (2013) doi: 10.1371/journal.pntd.0002475
- Guimaraes J.L., Lourie E.M.: The inhibition of some pharmacological actions of pentamidine by suramin. British Journal of Pharmacology and Chemotherapy. 6(3), 514 (1951) doi: 10.1111/j.1476-5381.1951.tb00663.x
- Gupta P., Singh K., Balodhi A., Jain K., Deeba F., Salam N.: Prevalence of Amoebiasis and Associated Complications in India: A Systematic Review. Acta Parasitologica. 67 (2022) doi: 10.1007/s11686-022-00547-z.
- Hajj R.E., Tawk L., Itani S., Hamie M., Ezzeddine J., El Sabban M., El Hajj H.: Toxoplasmosis: Current and Emerging Parasite Druggable Targets. Microorganisms. 9(12), 2531 (2021) doi: 10.3390/microorganisms9122531
- Hammershaimb E.A. and Berry A.A.: Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond. Expert Review of Vaccines. 23(1), 49–52 (2024) doi: 10.1080/14760584.2023.2292204
- Hassen J., Alemayehu G.S., Dinka H., Golassa L.: High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. Malaria Journal. 21(1), 286 (2022) doi: 10.1186/s12936-022-04304-5
- Herwaldt B.L., Berman J.D.: Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 46(3), 296–306 (1992) doi: 10.4269/ajtmh.1992.46.296
- Hung D.T., Tran L., Tam D.N.H., Elshafei G., Cuong N.T.K., Ha N.X., Khader S.A.E., Le Quang L., Shaikhkhalil H.W., Abdallfatah A., et al.: The prevalence of Pfk13 polymorphism in malaria patients treated with artemisinin-based therapy: a systematic review and meta-analysis. Parasitol Res. 123(5), 209 (2024) doi: 10.1007/s00436-024-08203-3
- Imwong M., Pukrittakayamee S., Looareesuwan S., Pasvol G., Poirreiz J., White N.J., Snounou G.: Association of Genetic Mutations in Plasmodium vivax dhfr with Resistance to Sulfadoxine-Pyrimethamine: Geographical and Clinical Correlates. Anti microbial Agents and Chemotherapy. 45(11), 3122–3127 (2001) doi: 10.1128/aac.45.11.3122-3127.2001
- Issa I., Lamine M.M., Hubert V., Ilagouma A., Adehossi E., Mahamadou A., Lobo N.F., Sarr D., Shollenberger L.M., Sandrine H., et al. Prevalence of Mutations in the Pfdhfr, Pfdhps, and Pfmdr1 Genes of Malarial Parasites Isolated from Symptomatic Patients in Dogondoutchi, Niger. Tropical Medicine and Infectious Disease. 7(8), 155 (2022) doi: 10.3390/tropicalmed7080155
- Jackson D., Salem A., Coombs G.H.: The invitro activity of metronidazole against strains of Escherichia coli with impaired DNA repair systems. Journal of Antimicrobial Chemotherapy. 13(3), 227–236 (1984) doi: 10.1093/jac/13.3.227
- Johnson A.M.: Toxoplasma: Biology, Pathology, Immunology, and Treatment. In: Coccidiosis of Man and Domestic Animals. CRC Press. 34 p. (1990)
- Jones J.L., Kruszon-Moran D., Elder S., Rivera H.N., Press C., Montoya J.G., McQuillan G.M.: Toxoplasma gondii Infection in the United States. Am J Trop Med Hyg. 98(2), 551–557 (2018) doi: 10.4269/ajtmh.17-0677
- Kalavani S, Matin S., Rahmanian V., Meshkin A., Bahadori Mazidi B., Taghipour A., Abdoli A.: Prevalence of Giardia duodenalis among African children: A systematic review and meta-analysis. Parasite Epidemiology and Control. 26, e00365 (2024) doi: 10.1016/j.parepi.2024.e00365
- Kaplan B., Kahn L.H., Monath T.P., Woodall J.: “ONE HEALTH” and parasitology. Parasites & Vectors. 2(1), 36 (2009) doi: 10.1186/1756-3305-2-36
- Koné M., Kaba D., Kaboré J., Thomas L.F., Falzon L.C., Koffi M., Kouamé C.M., Ahouty B., Compaoré C.F.A., N’Gouan E.K., et al.: Passive surveillance of human African trypanosomiasis in Côte d’Ivoire: Understanding prevalence, clinical symptoms and signs, and diagnostic test characteristics. PLOS Neglected Tropical Diseases. 15(8) e0009656 (2021) doi: 10.1371/journal.pntd.0009656
- de Koning H.P., Anderson L.F., Stewart M., Burchmore R.J.S., Wallace L.J.M., Barrett M.P.: The Trypanocide Diminazene Aceturate Is Accumulated Predominantly through the TbAT1 Purine Transporter: Additional Insights on Diamidine Resistance in African Trypanosomes. Antimicrobial Agents and Chemotherapy. 48(5), 1515–1519 (2004) doi: 10.1128/aac.48.5.1515-1519.2004
- Konstantinovic N, Guegan H, Stäjner T, Belaz S, Robert-Gangneux F. 2019. Treatment of toxoplasmosis: Current options and future perspectives. Food and Waterborne Parasitology. 15:e00036. doi:10.1016/j.fawpar.2019.e00036.
- Krakovka S., Ribacke U., Miyamoto Y., Eckmann L., Svärd S.: Characterization of Metronidazole-Resistant Giardia intestinalis Lines by Comparative Transcriptomics and Proteomics. Front Microbiol. 13 (2022) doi:
10.3389/fmicb.2022.834008 [accessed 2024 Aug 27]
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.834008/full - Lagunas-Rangel F.A., Yee J., Bermúdez-Cruz R.M.: An update on cell division of Giardia duodenalis trophozoites. Microbiological Research. 250, 126807 (2021) doi: 10.1016/j.micres.2021.126807
- Lapinskas P.J. and Ben-Harari R.R.: Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis. Postgraduate Medicine. 131(8), 589–596 (2019) doi: 10.1080/00325481.2019.1655258
- Makarov A., Began J., Mautone I.C., Pinto E., Ferguson L., Zoltner M., Zoll S., Field M.C.: The role of invariant surface glycoprotein 75 in xenobiotic acquisition by African trypanosomes. Microb Cell. 10(2), 18–35 (2023) doi: 10.15698/mic2023.02.790
- Mann S., Frasca K., Scherrer S., Henao-Martínez A.F., Newman S., Ramanan P., Suarez J.A.: A Review of Leishmaniasis: Current Knowledge and Future Directions. Curr Trop Med Rep. 8(2), 121–132 (2021) doi: 10.1007/s40475-021-00232-7
- Marques M.M., Costa M.R.F., Santana Filho F.S., Vieira J.L.F., Nascimento M.T.S., Brasil L.W., Nogueira F., Silveira H., Reyes-Lecca R.C., Monteiro W.M., et al.: Plasmodium vivax Chloroquine Resistance and Anemia in the Western Brazilian Amazon. Antimicrobial Agents and Chemotherapy. 58(1), 342–347 (2014) doi: 10.1128/aac.02279-12
- Matovu E., Stewart M.L., Geiser F., Brun R., Mäser P., Wallace L.J.M., Burchmore R.J., Enyaru J.C.K., Barrett M.P., Kaminsky R., et al.: Mechanisms of Arsenical and Diamidine Uptake and Resistance in Trypanosoma brucei. Eukaryotic Cell. 2(5), 1003–1008 (2003) doi: 10.1128/ec.2.5.1003-1008.2003
- McFadden D.C., Tomavo S., Berry E.A., Boothroyd J.C.: Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance. Molecular and Biochemical Parasitology. 108(1), 1–12 (2000) doi: 10.1016/S0166-6851(00)00184-5
- Meneceur P., Bouldouyre M.A., Aubert D., Villena I., Menotti J., Sauvage V., Garin J.F., Derouin F.: In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone. Antimicrob Agents Chemother. 52(4), 1269–1277 (2008) doi: 10.1128/AAC.01203-07
- Meshnick S.R. and Dobson M.J.: The History of Antimalarial Drugs. In: Rosenthal PJ, editor. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Totowa, NJ: Humana Press. p. 15–25 (2001) [accessed 2024 Sep 7]
https://doi.org/10.1007/978-1-59259-111-4_2 - Minbaeva G., Schweiger A., Bodosheva A., Kuttubaev O., Hehl A.B., Tanner I., Ziadinov I., Torgerson P.R., Deplazes P.: Toxoplasma gondii infection in Kyrgyzstan: seroprevalence, risk factor analysis, and estimate of congenital and AIDS-related toxoplasmosis. PLoS Negl Trop Dis. 7(2), e2043 (2013) doi: 10.1371/journal.pntd.0002043
- Monis P.T., Caccio S.M., Thompson R.C.A.: Variation in Giardia: towards a taxonomic revision of the genus. Trends in Parasitology. 25(2), 93–100 (2009) doi: 10.1016/j.pt.2008.11.006
- Moreira E.T. de S., Castro Faria Neto H.C. de, Reis P.A.: Chapter 17 – Cerebral malaria: Understanding the parasite pathogenesis in the brain. In: De Quevedo JL, Barichello T, Hasbun R, Dal-Pizzol F, editors. Neurobiology of Infectious Diseases. Academic Press. (Neurobiology of Disease). p. 291–304 (2025)
- Moss S., Mańko E., Krishna S., Campino S., Clark T.G., Last A.: How has mass drug administration with dihydroartemisininpiperaquine impacted molecular markers of drug resistance? A systematic review. Malar J. 21(1), 186 (2022) doi: 10.1186/s12936-022-04181-y
- Mukherjee A., Padmanabhan P.K., Singh S., Roy G., Girard I., Chatterjee M., Ouellette M., Madhubala R.: Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. Journal of Antimicrobial Chemotherapy. 59(2), 204–211 (2007) doi: 10.1093/jac/dkl494
- Munday J.C., Eze A.A., Baker N., Glover L., Clucas C., Aguinaga Andrés D., Natto M.J., Teka I.A., McDonald J., Lee R.S., et al. Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. Journal of Antimicrobial Chemotherapy. 69(3), 651–663 (2014) doi: 10.1093/jac/dkt442
- Munday J.C., Settimo L., de Koning H.P.: Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei. Front Pharmacol. 6 (2015) doi: 10.3389/fphar.2015.00032
- Naghavi M., Mestrovic T., Gray A., Hayoon A.G., Swetschinski L.R., Aguilar G.R., Weaver N.D., Ikuta K.S., Chung E., Wool E.E., et al.: Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Infectious Diseases. 24(8), 868–895 (2024) doi: 10.1016/S1473-3099(24)00158-0
- Nok A.J.: Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res. 90(1), 71–79 (2003) doi: 10.1007/s00436-002-0799-9
- Noronha M., Pawar V., Prajapati A., Subramanian R.B.: A literature review on traditional herbal medicines for malaria. South African Journal of Botany. 128 292–303 (2020) doi: 10.1016/j.sajb.2019.11.017
- Nsobya S.L., Dokomajilar C., Joloba M., Dorsey G., Rosenthal P.J.: Resistance-Mediating Plasmodium falciparum pfcrt and pfmdr1 Alleles after Treatment with Artesunate-Amodiaquine in Uganda. Antimicrobial Agents and Chemotherapy. 51(8), 3023–3025 (2007) doi: 10.1128/aac.00012-07
- O’Neill P.M., Barton V.E., Ward S.A.: The molecular mechanism of action of artemisinin-the debate continues. Molecules. 15(3), 1705–1721 (2010) doi: 10.3390/molecules15031705
- Pacheco M.A., Schneider K.A., Cheng Q., Munde E.O., Ndege C., Onyango C., Raballah E., Anyona S.B., Ouma C., Perkins D.J., et al. Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H. Malar J. 19(1), 378 (2020) doi: 10.1186/s12936-020-03454-8
- Patel P., Bharti P.K., Bansal D., Ali N.A., Raman R.K., Mohapatra P.K., Sehgal R., Mahanta J., Sultan A.A., Singh N.: Prevalence of mutations linked to antimalarial resistance in Plasmodium falciparum from Chhattisgarh, Central India: A malaria elimination point of view. Sci Rep. 7(1), 16690 (2017) doi: 10.1038/s41598-017-16866-5
- Pérez-Victoria J.M., Bavchvarov B.I., Torrecillas I.R., Martínez-García M., López-Martín C., Campillo M., Castanys S., Gamarro F.: Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. Antimicrob Agents Chemother. 55(8), 3838–3844 (2011) doi: 10.1128/AAC.00065-11
- Perry D., Dixon K., Garlapati R., Gendernalik A., Poché D., Poché R.: Visceral Leishmaniasis Prevalence and Associated Risk Factors in the Saran District of Bihar, India, from 2009 to July of 2011. Am J Trop Med Hyg. 88(4), 778–784 (2013) doi: 10.4269/ajtmh.12-0442
- Pinart M., Rueda J.R., Romero G.A., Pinzón-Flórez C.E., Osorio-Arango K., Silveira Maia-Elkhoury A.N., Reveiz L., Elias V.M., Tweed J.A.: Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2020(8), CD004834 92020) doi: 10.1002/14651858.CD004834.pub3
- Pluijm R.W. van der, Amaratunga C., Dhorda M., Dondorp A.M.: Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm? Trends in Parasitology 37(1), 15–24 (2021) doi: 10.1016/j.pt.2020.09.011
- Ponte-Sucre A., Gamarro F., Dujardin J.C., Barrett M.P., López-Vélez R., García-Hernández R., Pountain A.W., Mwenechanya R., Papadopoulou B.: Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLOS Neglected Tropical Diseases 11(12), e0006052 (2017) doi: 10.1371/journal.pntd.0006052
- Potvin J.E., Leprohon P., Queffeulou M., Sundar S., Ouellette M.: Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani. Clin Infect Dis. 72(10), e526–e532 (2020) doi: 10.1093/cid/ciaa1236
- Pountain A.W., Weidt S.K., Regnault C., Bates P.A., Donachie A.M., Dickens N.J., Barrett M.P.: Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites. PLoS Negl Trop Dis. 13(2), e0007052 (2019) doi: 10.1371/journal.pntd.0007052
- Prusa A.R., Kasper D.C., Pollak A., Olischar M., Gleiss A., Hayde M.: Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program. Clinical Microbiology and Infection. 21(2), 191.e1–191.e8 (2015) doi: 10.1016/j.cmi.2014.09.018
- Pulcini S., Staines H.M., Lee A.H., Shafik S.H., Bouyer G., Moore C.M., Daley D.A., Hoke M.J., Altenhofen L.M., Painter H.J., et al.: Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite’s food vacuole and alter drug sensitivities. Sci Rep. 5(1), 14552 (2015) doi: 10.1038/srep14552
- Reed M.B., Saliba K.J., Caruana S.R., Kirk K., Cowman A.F.: Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 403(6772), 906–909 (2000) doi: 10.1038/35002615
- Rénia L. and Goh Y.S.: Malaria Parasites: The Great Escape. Front Immunol. 7 (2016) doi: 10.3389/fimmu.2016.00463
- Riches A., Hart C.J.S., Trenholme K.R., Skinner-Adams T.S.: Anti-Giardia Drug Discovery: Current Status and Gut Feelings. J Med Chem. 63(22), 13330–13354 (2020) doi: 10.1021/acs.jmedchem.0c00910
- Robert-Gangneux F., Murat J.B., Fricker-Hidalgo H., Brenier-Pinchart M.P., Gangneux J.P., Pelloux H.: The placenta: a main role in congenital toxoplasmosis? Trends Parasitol. 27(12), 530–536 (2011) doi: 10.1016/j.pt.2011.09.005
- Rodrigo C., Rajapakse S., Fernando D.: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2020(9), CD010458 (2020) doi: 10.1002/14651858.CD010458.pub3
- Roro G.B., Eriso F., Al-Hazimi A.M., Kuddus M., Singh S.C., Upadhye V., Hajare S.T.: Prevalence and associated risk factors of Entamoeba histolytica infection among school children from three primary schools in Arsi Town, West Zone, Ethiopia. J Parasit Dis. 46(3), 776–784 (2022) doi: 10.1007/s12639-022-01495-1
- SA Maternal & Neonatal Clinical Network. South Australian Perinatal Practice Guidelines toxoplasmosis in pregnancy. (2015)
- Sands M., Kron M.A., Brown R.B.: Pentamidine: A Review. Reviews of Infectious Diseases. 7(5), 625–6344 (1985) doi: 10.1093/clinids/7.5.625
- Sasidharan S. and Saudagar P.: Leishmaniasis: where are we and where are we heading? Parasitol Res. 120(5), 1541–1554 (2021) doi: 10.1007/s00436-021-07139-2
- Sawyer P.R., Brogden R.N., Pinder R.M., Speight T.M., Avery G.S.: Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs. 11(6), 423–440 (1976) doi: 10.2165/00003495-197611060-00003
- Schousboe M.L., Ranjitkar S., Rajakaruna R.S., Amerasinghe P.H., Morales F., Pearce R., Ord R., Leslie T., Rowland M., Gadalla N.B, et al. Multiple Origins of Mutations in the mdr1 Gene-A Putative Marker of Chloroquine Resistance in P. vivax. PLOS Neglected Tropical Diseases. 9(11), e0004196 (2015) doi: 10.1371/journal.pntd.0004196
- Semedo M.G., Pereira A.L., Pita J.R.: The influence of German science on Cinchona and quinine research in Portugal in the second half of the 19th century. Pharmazie. 76(8), 396–402 (2021) doi: 10.1691/ph.2021.1050
- Servián A., Helman E., Iglesias M. del R., Panti-May J.A., Zonta M.L., Navone G.T.: Prevalence of Human Intestinal Entamoeba spp. in the Americas: A Systematic Review and Meta-Analysis 1990–2022. Pathogens. 11(11), 1365 (2022) doi: 10.3390/pathogens11111365
- Sharpton T.J., Combrink L., Arnold H.K., Gaulke C.A., Kent M.: Harnessing the Gut Microbiome in the Fight against Anthelminthic Drug Resistance. Curr Opin Microbiol. 53, 26–34 (2020) doi: 10.1016/j.mib.2020.01.017
- Silva L.A., Reis-Cunha J.L., Bartholomeu D.C., Vítor R.W.A.: Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil. PLOS ONE 12(1), e0170689 (2017) doi: 10.1371/journal.pone.0170689
- Singh A., Banerjee T., Shukla S.K., Upadhyay S., Verma A.: Creep in nitroimidazole inhibitory concentration among the Entamoeba histolytica isolates causing amoebic liver abscess and screening of andrographolide as a repurposing drug. Sci Rep. 13(1), 12192 (2023) doi: 10.1038/s41598-023-39382-1
- Singh A., Houpt E., Petri W.A.: Rapid Diagnosis of Intestinal Parasitic Protozoa, with a Focus on Entamoeba histolytica. Interdisciplinary Perspectives on Infectious Diseases 2009(1), 547090 (2009) doi: 10.1155/2009/547090
- Sosa N., Pascale J.M., Jiménez A.I., Norwood J.A., Kreishman-Detrick M., Weina P.J., Lawrence K., McCarthy W.F., Adams R.C., Scott C., et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 13(5), e0007253 (2019) doi: 10.1371/journal.pntd.0007253
- Srivastava S., Mishra J., Gupta A.K., Singh A., Shankar P., Singh S.: Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Parasit Vectors. 10, 49 (2017) doi: 10.1186/s13071-017-1969-z
- Staines H.M., Burrow R., Teo B.H.Y., Chis Ster I., Kremsner P.G., Krishna S.: Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. J Antimicrob Chemother. 73(3), 581–595 (2018) doi: 10.1093/jac/dkx431
- Steverding D.: The spreading of parasites by human migratory activities. Virulence. 11(1), 1177–1191 (2020) doi: 10.1080/21505594.2020.1809963
- Takala-Harrison S., Jacob C.G., Arze C., Cummings M.P., Silva J.C., Dondorp A.M., Fukuda M.M., Hien T.T., Mayxay M., Noedl H., et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 211(5), 670–679 (2015) doi: 10.1093/infdis/jiu491
- Tharmaratnam T., Kumanan T., Iskandar M.A., D’Urzo K., Gopee-Ramanan P., Loganathan M., Tabobondung T., Tabobondung T.A., Sivagurunathan S., Patel M., et al. Entamoeba histolytica and amoebic liver abscess in northern Sri Lanka: a public health problem. Trop Med Health. 48(1), 2 (2020) doi: 10.1186/s41182-020-0193-2
- Tjitra E., Baker J., Suprianto S., Cheng Q., Anstey N.M.: Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations. Antimicrob Agents Chemother. 46(12), 3947–3953 (2002) doi: 10.1128/AAC.46.12.3947-3953.2002
- Torgerson P.R. and Mastroiacovo P.: The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 91(7), 501–508 (2013) doi: 10.2471/BLT.12.111732
- Tripathi L.K., Nailwal T.K.: Chapter 1 – Leishmaniasis: an overview of evolution, classification, distribution, and historical aspects of parasite and its vector. In: Samant M, Chandra Pandey S, editors. Pathogenesis, Treatment and Prevention of Leishmaniasis. Academic Press. p. 1–25 (2021)
https://www.sciencedirect.com/science/article/pii/B9780128228005000044 - Tse E.G., Korsik M., Todd M.H.: The past, present and future of antimalarial medicines. Malaria Journal. 18(1), 93 (2019) doi: 10.1186/s12936-019-2724-z
- Ungogo M.A., Campagnaro G.D., Alghamdi A.H., Natto M.J., de Koning H.P.: Differences in Transporters Rather than Drug argets Are the Principal Determinants of the Different Innate Sensitivities of Trypanosoma congolense and Trypanozoon Subgenus Trypanosomes to Diamidines and Melaminophenyl Arsenicals. International Journal of Molecular Sciences 23(5), 2844 (2022) doi: 10.3390/ijms23052844
- Waithera M.W., Sifuna M.W., Kimani S.K., Takei M.:. Drug selection pressure and fitness cost for artemether-resistant Plasmodium berghei ANKA parasites in vivo. International Journal of Antimicrobial Agents 62(6), 107012 (2023) doi: 10.1016/j.ijantimicag.2023.107012
- WHO. 2020. Sustained decline in sleeping sickness cases puts elimination within reach. [accessed 2024 Oct 4].
https://www.who.int/news/item/23-06-2020-sustained-decline-in-sleeping-sickness-cases-puts-elimination-within-reach . - Wicht K.J., Mok S., Fidock D.A.: Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annual Review of Microbiology. 74, 431–454 (2020) doi: 10.1146/annurev-micro-020518-115546
- Wijnant G.J, Dumetz F., Dirkx L., Bulté D., Cuypers B., Van Bocxlaer K., Hendrickx S.: Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. Front Trop Dis. 3 (2022) doi: 10.3389/fitd.2022.837460
- WHO. 2024a. Leishmaniasis. [accessed 2024 Aug 26].
https://www.who.int/news-room/fact-sheets/detail/leishmaniasis . - WHO. 2024b. Guidelines for the treatment of human African trypanosomiasis.[accessed 2024 Sep 3].
https://www.who.int/publications/i/item/9789240096035 . - WHO. 2023. World Malaria Report 2023. [accessed 2024 Aug 26].
https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023 . - Xie S.C., Ralph S.A., Tilley L.:. K13, the Cytostome, and Artemisinin Resistance. Trends Parasitol. 36(6), 533–544 (2020) doi: 10.1016/j.pt.2020.03.006
- Yoshida N., Yamauchi M., Morikawa R., Hombhanje F., Mita T.: Increase in the proportion of Plasmodium falciparum with kelch13 C580Y mutation and decline in pfcrt and pfmdr1 mutant alleles in Papua New Guinea. Malar J. 20(1), 410 (2021) doi: 10.1186/s12936-021-03933-6
- Zajaczkowski P., Lee R., Fletcher-Lartey S.M., Alexander K., Mahimbo A., Stark D., Ellis J.T.: The controversies surrounding Giardia intestinalis assemblages A and B. Current Research in Parasitology & VectorBorne Diseases 1, 100055 (2021) doi: 10.1016/j.crpvbd.2021.100055
- Zoltner M., Campagnaro G.D., Taleva G., Burrell A., Cerone M., Leung K.F., Achcar F., Horn D., Vaughan S., Gadelha C., et al. Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes. Journal of Biological Chemistry. 295(24), 8331–8347 (2020) doi: 10.1074/jbc.RA120.012355
Language: English, Polish
Page range: 24 - 38
Submitted on: Oct 5, 2024
Accepted on: Feb 12, 2025
Published on: May 8, 2025
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2025 Fadi M. Baakdah, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.